UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
|
|
- Arabella York
- 5 years ago
- Views:
Transcription
1 page 1 / 6
2 EDITORIAL BOARD EDITORIAL BOARD Patrons Rector, Airlangga University Dean, Airlangga University School of Medicine Director, Dr Soetomo Hospital Surabaya Founder Prof R Soedarso Djojonegoro, MD Chairman Prof Askandar Tjokroprawiro, MD, PhD Vice-Chairman Prof M Sajid Darmadipura, MD Editor-in-Chief Prof Suhartono Taat Putra, MD, MS, PhD Vice Editor-in-Chief Prof Doddy M Soebadi, MD, PhD Senior Editors Prof Soetjipto, MD, MS, PhD Prof Widjoseno Gardjito, MD Prof Rachmat Santoso, MD Prof Benjamin Chandra, MD, PhD Prof R Moeljono Notosoedirdjo, MD, PhD Prof Purnomo Suryohudoyo, MD Prof Soedijono, MD, PhD Prof Dr med Puruhito, MD Prof Eddy Rahardjo, MD, PhD International Editors Prof HJA Mensink, MD, PhD Prof Sangkot Marzuki, MD, PhD Prof Yasuhiko Tomino, MD, PhD Prof Tikki Pangestu, PhD Prof Aw Tar Choon, MBBS, Mmed (Int.Med), MRC FRCPA, MPP Members Prof Djoko Roeshadi, MD, PhD Prof Benjamin P Margono, MD, PhD Prof Moersintowarti B Narendra, MD, MSc Prof Subijanto Marto Sudarmo, MD, PhD Aucky Hinting, MD, PhD R Darmawan Setijanto, DDS, MS, PhD Prof Parwati Setiono Basuki, MD, MSc, DTM&H Maria Yolanda Probohoesodo, MD Agus Darwanto, Drs, MS, PhD Managing Editors page 2 / 6
3 Suharto MD, MSc, DTM&H, PhD Joewono Soeroso, MD, MSc, PhD Endang Joewarini, MD, PhD Consultants Prof Haryono Suyono, PhD Prof Marsetio Donosepoetro, MD, PhD Prof Karjadi Wirjoatmodjo, MD Prof D Ma rifin Husin, MD, MSc Prof Eddy Soewandojo, MD Triono Soendoro, MD, PhD International Communication Dripa Sjabana, MD, MS Executive Secretaries Sunarko Setyawan, MD, MS, PhD Sri Musta ina, Drs, MS Mochammad Zuhdy, Drs Marketing and Subscription Prof Rochmad Romdoni, MD, PhD Urip Murtedjo, MD Agung Prasmono, MD Poedjo Hartono, MD Fund Raising Prof Boediwarsono, MD Agus Harianto, MD Suhartono DS, MD Treasurer Slamet Soeharto, Ir page 3 / 6
4 Table of Contents No Title Page 1 THE EFFECTIVENESS OF TOPICAL GARLIC EXTRACT FOR METHICILLIN RESISTANT Staphylococcus aureus TREATMENT IN BURNS 2 Mycobacterium tuberculosis IMMUNOGLOBULIN M (IgM) AND IMMUNOGLOBULIN G (IgG) SURVEY IN HIV-INFECTED DONORS 3 COMPARING THE EFFECT OF RED YEAST RICE, DATE PALM, AND GUAVA LEAF EXTRACT ON THROMBOCYTE AND MEGAKARYOCYTE COUNT IN THROMBOCYTOPENIC WHITE RATS 4 MATERNALLY INHERITED NUCLEOTIDE VARIATION OF MITOCHONDRIAL DNA (mtdna) D-LOOP REGION 126 pb (nt: HVS II) IN MADURESE INDIVIDUALS 5 RAPID CULTURE METHOD USING BIPHASIC MEDIA ON BACTERIOLOGIC DIAGNOSIS TO DETECT Mycobacterium tuberculosis FOR DETERMINING PULMONARY TUBERCULOSIS 6 EFFECT OF CARBIDE AND CaCl2 CONCENTRATION ON VITAMIN C CONTENTS OF BANANA KEPOK 7 DIRECT CLONING OF MELANOMA ANTIGEN 1 (MAGE-1) AND THE E2 GENE OF HOG CHOLERA VIRUS (HCV) FROM THE BLUNT END PCR PRODUCT USING pet 101/D-TOPO QUANTITATION OF MICROORGANISMS IN LOWER RESPIRATORY TRACT SECRETIONS BMD-QUS ASSESSMENT RESULT APPROPRIATES TO DIAGNOSE OSTEOPOROSIS ACID-FAST BACTERIA M. leprae EXAMINATION IN LEPROSY PATIENTS BEFORE AND AFTER TREATMENT DIAGNOSTIC ROLE OF INTRA OPERATIVE OVARIAN CYST FLUID CYTOLOGY IN DETERMINING MALIGNANCY CORRELATION BETWEEN ADOLESCENTS' KNOWLEDGE ON DRUGS HAZARD AND THEIR BEHAVIOR IN DRUG ABUSE IN TULUNGAGUNG BASAL INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSE-LOWERING DRUGS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY PUBLIC HEALTH CENTER page 4 / 6
5 Vol No. 2 / TOC : 13, and page : BASAL INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSE-LOWERING DRUGS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY PUBLIC HEALTH CENTER BASAL INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSE-LOWERING DRUGS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY PUBLIC HEALTH CENTER Author : Hermina Novida - Agung Pranoto - Jongky Hendro Prayitno - Askandar Tjokroprawiro - Abstract Effective glycemic control is very important to minimize longterm complications of type 2 diabetes mellitus (DM). However, it is welldocumented that many patients spend prolonged periods above optimal glycaemic range, especially in primary public health centers.most of primary care physicians, who are responsible to manage them, delay to iniate insulin therapy for some reasons. The aim ofthis study was to evaluate efficacy and safety of insulin detemir added to oral therapy in insulin-naive individuals with type 2 DM.This one group pre- and post-test study involved insulin-naive and previously oral-treated DM patients (n=64, HbA1c> 8.0%),drawn from 10 primary public health center centers all over Surabaya, Indonesia, using simple random sampling method. Patientswere treated with insulin detemir for 12 weeks and insulin doses were titrated to target fasting plasma glucose (FPG) < 125 mg/dl.outcomes evaluated included HbA1c, level of fasting and 2 hours post-prandial glucose, risk of hypoglycemia and body weight. After12 weeks, HbA1c had decreased by 2.53% (from 11.38% to 8.85%) with detemir insulin once a day (p=0.001). FPG improved from mg/dl to mg/dl (p=0.001) and 2 hour post-prandial glucose improved from mg/dl to mg/dl (p=0.001).frequency of hypoglycaemia events were 6.4% (4 hypoglycaemic events) and all cases were mild events so that they did not need tobe admitted in the hospital. Hypoglycaemic events can be treated by the patients themselves with sugar and food intake, and then thedose of detemir insulin was adjusted. Besides hypoglyecemic events, no other side effects were recorded. Mean the pre insulintherapy BMI was ± 4.22 kg/m2 to become ± 5.60 kg/m 2 at the end of the study. There was a decrease in body weightbefore and after insulin detemir therapy, but it was not statistically significant (p 0.37, 95% CI ). In conclusion, theaddition of basal insulin to oral antidiabetic drugs in poorly controlled type 2 diabetes patients in primary public health centerachieved clinically improvements in glycaemic control with low risks of hypoglycaemia and non-significant body weightincrease.(fmi 2013;49: ) Keyword : basal, insulin, add-on, therapy, oral, antidiabetics, glycaemia, type, 2, Daftar Pustaka : 1. Hermansen K, Lund P, Clemmensen K, Breum L, Moller KM, Rosenfalk AM, (2007). 3-months results from denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE Study. - : The Review of Diabetes Study 2. Hirsch IB, Bergenstal RM, Parkin CG, Wright Jr E, Buse JB, (2005). A real world approach to insulin therapy in primary care practice. - : Clin Diabetes page 5 / 6
6 Powered by TCPDF ( UNIVERSITAS AIRLANGGA Copy alamat URL di bawah ini untuk download fullpaper : journal.unair.ac.id/filerpdf/fmi5887bc14e8full.pdf page 6 / 6
UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD Patrons Rector, Airlangga University Dean, Airlangga University School of Medicine Director, Dr Soetomo Hospital Surabaya Founder Prof R Soedarso Djojonegoro,
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD empty page 2 / 5 Table of Contents No Title Page 1 SCLERAXIS AS DETERMINANT OF TENDON CELL DENSITY IN ACHILLES TENDON HEALING TREATED WITH MESENCHYMAL STEM CELL IN RABBIT 2 THE
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Patron : Dean
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Patron : Dean
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationFrequency of Metabolic Syndrome on Diabetes Mellitus Patients in Surabaya
Biomolecular and Health Science Journal Vol 1 No 1 (2018), April 2018 ORIGINAL ARTICLE Frequency of Metabolic Syndrome on Diabetes Mellitus Patients in Surabaya Dyah Peni Puspitasari 1, Budi Widodo 2,
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 6 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Patron : Dean
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationJ. Basic. Appl. Sci. Res., 4(12) , , TextRoad Publication
2014, TextRoad Publication ISSN 2090-4304 Journal of Basic and Applied Scientific Research www.textroad.com Expert System for Blood Glucose Fluctuations Measurement Based on MAGE (Mean Amplitude of Glycemic
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationORIGINAL ARTICLE. Use of Freestyle Libre Pro TM Flash Glucose Monitoring System in Different Clinical Situations at a Diabetes Centre
18 Journal of The Association of Physicians of India Vol. 65 August 217 ORIGINAL ARTICLE Use of Freestyle Libre Pro TM Flash itoring System in Different Clinical Situations at a Diabetes Centre Bangalore
More informationInsulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
More informationPeer Review Report. [long acting insulin analogues glargine and detemir]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [long acting insulin analogues glargine and detemir] (1) Does the application adequately address the issue of the public
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Patron : Dean
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNumber of patients: Planned: 403 Randomized: 391 Treated: 390 Efficacy: 363 (Full analysis set) 356 (Per-protocol set)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company : sanofi-aventis
More informationSetting The setting was outpatient, secondary care. The economic study was carried out in the UK.
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK Palmer A J, Valentine W J, Ray J A, Foos V, Lurati F, Smith I, Lammert
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Patron : Dean
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationIs Degludec the Insulin of Tomorrow?
5 : 6 Nihal Thomas, Ron Thomas Varghese, Vellore Abstract In an effort to develop better basal insulin with a profile that may cause less hypoglycaemia, ludec an analogue with a decanoic acid side chain
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationMedium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
Drugs R D (214) 14:133 138 DOI 1.17/s4268-14-48-6 ORIGINAL RESEARCH ARTICLE Medium-Term Effects of Insulin ludec on Patients with Type 1 Diabetes Mellitus Rie Nakae Yoshiki Kusunoki Tomoyuki Katsuno Masaru
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationInsulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )
Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Toujeo uses the same
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationSanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes
PRESS RELEASE Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes Dublin, Ireland (15 June 2012) Sanofi presented results
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationThe hallmark of type 2 diabetes mellitus (T2DM) is progressive
16 SUPPLEMENT TO JAPI january 2013 VOL. 61 Original Article Initiating Therapy or Switching to Biphasic Insulin Aspart Improves Glycaemic Control in Type 2 Diabetes: An Indian Experience from the A 1 chieve
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationDIABETES WORKSHOP EMEA Improved treatments : medication for children/adolescents with diabetes mellitus
DIABETES WORKSHOP EMEA Improved treatments : medication for children/adolescents with diabetes mellitus Aim: to identify the best possible research approaches for new medication in the field of diabetes
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationDIABETES WITH PREGNANCY
DIABETES WITH PREGNANCY Prof. Aasem Saif MD,MRCP(UK),FRCP (Edinburgh) Maternal and Fetal Risks Diabetes in pregnancy is associated with risks to the woman and to the developing fetus. Maternal and Fetal
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationSetting The setting was primary care. The economic study was carried out in the USA.
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Umpierrez G, Issa M, Vlajnic
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationCurrent Trends in Diagnosis and Management of Gestational Diabetes
Current Trends in Diagnosis and Management of Gestational Diabetes Shreela Mishra, MD Assistant Clinical Professor UCSF Fresno Medical Education Program 2/2/2019 Disclosures No disclosures 2/2/19 Objectives
More informationSanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018
Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018 Background: For people with diabetes the early months of treatment with long-acting insulin are important for
More informationADA Analyst Presentation Saturday 9 th June
ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationCONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b
CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario Antonio Ceriello a,b Excessive Glucose Fluctuations With Same A1C Values 400 Mean A1C = 6.7% Glucose Concentration (mg/dl) 300
More informationiglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationSoliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow
Soliqua 100/33 (insulin glargine, lixisenatide) New Product Slideshow Introduction Brand name: Soliqua 100/33 Generic name: Insulin glargine (rdna origin), lixisenatide Pharmacological class: Human insulin
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationUse of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials
primary care diabetes 10 (2016) 51 59 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Original research Use of a basal-plus insulin
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Patron : Dean
More informationREF/2011/11/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 24 Nov 2017 03:47:32 GMT) CTRI Number Last Modified On 15/01/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationInsulin pumps (CSII): Using Modern technology to communicate with families of children with type 1 diabetes
Insulin pumps (CSII): Using Modern technology to communicate with families of children with type 1 diabetes Grace Harris and Rita Sigley Paediatric Diabetes Nurse Specialists Starship children s Health
More informationDiabetes Care Publish Ahead of Print, published online June 1, 2009
Diabetes Care Publish Ahead of Print, published online June 1, 2009 Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationStudies on impact of diabetes mellitus on tuberculosis in coastal region of Andhra Pradesh
Available online at www.pelagiaresearchlibrary.com Advances in Applied Science Research, 2013, 4(1):458-462 ISSN: 0976-8610 CODEN (USA): AASRFC Studies on impact of diabetes mellitus on tuberculosis in
More informationGestational Diabetes in Resouce. Prof Satyan Rajbhandari (RAJ)
Gestational Diabetes in Resouce Limited Area Prof Satyan Rajbhandari (RAJ) Case History RP, 26F Nepali girl settled in the UK Primi Gravida BMI: 23 FH of type 2 DM 75 gm Glucose OGTT in week 25 0 Min
More informationUK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1
PRESS RELEASE 24 th February, 2014 UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1 London, 24 February 2014
More informationBy Betsy B. Dokken, PhD, NP, CDE. Keywords: diabetes mellitus, insulin analogues, insulin therapy
How insulin analogues can benefit patients Abstract: Primary care providers offer diabetes care for many patients in the United States. Primary care nurse practitioners can benefit from an understanding
More informationSwitching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes
Diabetes Management Switching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes Myrey Siuffi D* ABSTRACT Introduction: Degludec (Ideg) is an ultra-long
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationBreaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes
Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Taking It to the Next Level: Pearls for Your Clinical Practice Thursday, April 23, 2009 6:00 AM - 8:00
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationChairman s Rounds, 02/15/2011
Chairman s Rounds, 02/15/2011 Edward Lipkin, MD Associate Professor, Department of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington Predictive factors in patient s
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationReceived 10 September 2014; revised 8 October 2014; accepted 3 November 2014
Journal of Diabetes Mellitus, 2014, 4, 379-387 Published Online November 2014 in SciRes. http://www.scirp.org/journal/jdm http://dx.doi.org/10.4236/jdm.2014.44051 Biphasic Insulin Aspart 30 Therapy in
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationSupplementary Online Content
Supplementary Online Content Lind M, Polonsky W, Hirsch IB, et al. Effect of continuous glucose monitoring vs conventional therapy on glycemic control among patients type 1 diabetes treated multiple daily
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationCharles Darwin University
Charles Darwin University Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes an analysis of data from the Diabetes Control and Complications Trial Maple-Brown,
More informationInsulin analogues Das PP, Datta PG
The ORION Medical Journal 2007 Sep;28:497-500 Insulin analogues Das PP, Datta PG Introduction Diabetes mellitus is a very big challenge for our medical science. To overcome this problem we need newer generation
More informationUNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya
page 1 / 5 EDITORIAL BOARD EDITORIAL BOARD OF DENTAL JOURNAL (MAJALAH KEDOKTERAN GIGI), January 2nd, 2014 December 31st, 2014 SK: 166/H3.1.2/KD/2014 January 2 nd, 2014 December 31 st, 2014 Chief Editor
More informationRole of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD
Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD International Diabetes Center and Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationLatest Nutritional Guidelines: What s new for practice? Paul Pipe-Thomas Specialist Dietitian
+ Latest Nutritional Guidelines: What s new for practice? Paul Pipe-Thomas Specialist Dietitian + Evidence Based Guidelines Last nutritional guidelines published in 2003. New guidelines published in May
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationDüsseldorf, Germany 24 th February, Response from Bernd Richter, written in his personal capacity, to the
Düsseldorf, Germany 24 th February, 2017 Response from Bernd Richter, written in his personal capacity, to the Essential Medicines List (EML) 2017 Application for the inclusion of long acting insulin analogues
More informationTeam-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals
Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals 1. Which one of the agents listed here is widely considered the first-line therapy in type 2 diabetes
More informationLe incretine: un passo avanti. Francesco Dotta
Le incretine: un passo avanti Francesco Dotta U.O.C. Diabetologia, Policlinico Le Scotte Università di Siena Fondazione Umberto Di Mario ONLUS Toscana Life Science Park Incretins: multiple targets multiple
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More information